CompletedPhase 2

Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)

United States5 participantsStarted 2023-10-03

Plain-language summary

An Open-Label, Proof-Of-Concept, Study of Baricitinib for the Treatment of Pyoderma Gangrenosum

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Healing

Timeframe: Week 24

NCT IDNCT04901325

SponsorOregon Health and Science University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-01-05